The magnitude of early hepatitis B RNA and DNA declines directly inform capsid assembly modulator effectiveness

For millions of people living with chronic hepatitis B, the virus is a silent, persistent guest in the liver. While vaccines can prevent infection, there is no simple cure for those already infected, and current treatments often require a lifetime of daily medication just to keep the virus in check. The goal of modern medicine is to find a "functional cure," a treatment that clears the virus so completely that a patient can stop taking drugs without the infection returning. To get there, scientists are testing new drugs called capsid assembly modulators. These drugs work by jamming the viral machinery inside liver cells, preventing the virus from building the protective shells it needs to replicate. However, a major hurdle remains: researchers have no simple way to know how well these new drugs are actually working inside a human body during the early stages of testing. Without this knowledge, they cannot tell if a drug is strong enough to be a cure or if it is too weak to matter, and they risk exposing patients to long trials where the virus might learn to resist the medicine.

A team of researchers at Los Alamos National Laboratory has now found a way to solve this puzzle by watching how the virus behaves in the first two weeks of treatment. They focused on two specific types of measurements that doctors can easily take from a patient's blood: the amount of viral genetic material known as HBV RNA and the amount of viral DNA. By studying data from recent clinical trials of two different drugs, the researchers discovered that the speed and size of the drop in these two substances during the first phase of treatment directly reveal how effectively the drug is blocking the virus. They built a detailed computer model of the infection process to track what happens inside the body, from the moment the drug is taken to the moment the virus levels in the blood begin to fall. This model allowed them to connect the visible changes in the blood to the invisible actions of the drug inside the liver cells.

The researchers analyzed data from two separate clinical trials involving nearly sixty participants who took either vebicorvir or ABI-H2158. These trials were designed to test different doses of the drugs over short periods, typically lasting two to four weeks. The team fed the blood test results from these participants into their mathematical model, which tracks the life cycle of the virus. They found that when the drug works, the levels of HBV RNA and HBV DNA in the blood do not just drop randomly; they fall in a very specific, two-step pattern. The first step is a rapid decline that happens quickly after the drug is introduced. The researchers realized that the size of this initial drop is a direct measure of how much the drug is stopping the virus from making new copies. If the drug is highly effective, the drop is large. If the drug is weak, the drop is small.

To prove this connection, the team looked at the exact moment when the rapid drop slowed down and transitioned into a slower, second phase of decline. Their model showed that the ratio of the viral levels at the start of treatment compared to the levels at this transition point is mathematically equal to the drug's effectiveness. In simpler terms, if the viral levels drop by a certain amount before the pace changes, that amount tells you exactly what percentage of the virus's production the drug has blocked. They tested this idea by comparing the model's predictions against the actual data from the trials. The results were striking: the drop in viral levels observed just seven days after starting treatment was enough to predict the drug's effectiveness with extreme precision. For example, they found that a drop of one unit on the logarithmic scale used to measure these viruses corresponds to the drug blocking ninety percent of viral production, while a drop of two units corresponds to blocking ninety-nine percent.

This finding is significant because it means scientists do not need to wait for months or years to see if a new drug is working. They can determine the potency of a new capsid assembly modulator after just two weeks of treatment. The researchers used computer simulations to show that this method works even for hypothetical future drugs that are far more powerful than the ones currently tested. In these simulations, they created a virtual trial with a drug that was fifty times more effective than the best current candidate. The method successfully distinguished this super-strong drug from the existing ones based solely on the viral decline measured at day fourteen. This suggests that very short clinical trials could be used to screen new drugs, allowing researchers to identify the most promising candidates quickly.

The study also highlighted a subtle difference between the two drugs tested. While both were effective at blocking the virus, the model revealed that one drug, ABI-H2158, caused the infected liver cells to die slightly faster than the other. This faster cell death was linked to a rise in a liver enzyme called ALT, which is a sign of liver stress. The model detected this increased cell death within the first two weeks, even before the clinical trial was stopped due to safety concerns. This demonstrates that the mathematical approach can spot potential safety issues early, providing a clearer picture of both the benefits and risks of a new treatment.

Ultimately, the work provides a clear, practical rule for the future of hepatitis B research. By simply measuring how much the viral RNA and DNA levels fall in the first two weeks of treatment, researchers can calculate exactly how well a new drug is working. This removes the guesswork from early drug development and offers a faster, safer path to finding a functional cure. Instead of waiting to see if the virus eventually disappears, doctors and scientists can now look at the early decline and know immediately if they have found a drug strong enough to change the course of the disease.